Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accum...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

StockMarketGuru Apr. 17 at 4:24 PM

$PRME oh?

0 · Reply

JasonCO Apr. 17 at 4:00 PM

$PRME

0 · Reply

Elamenape2 Apr. 17 at 3:54 PM

$PRME

0 · Reply

arg195 Apr. 17 at 3:09 PM

$PRME SPY up 7% past 6 months, PRME down 30% same period

1 · Reply

Mcnulty_jimmy Apr. 17 at 2:47 PM

$PRME Daily Deion

0 · Reply

Mindegap Apr. 17 at 2:37 PM

$MGX Great News: $MGX created a tool that for the first time combines AAV-compatible size with therapeutic-grade editing efficiency — unlocking in vivo gene editing for tissues outside the liver that have been effectively unreachable until now. This enables next-generation editors that currently can't fit in AAV at all. Published in Nature. $PRME $BEAM

0 · Reply

DragonAlgo Apr. 17 at 8:37 AM

🐉 $PRME PUT — DragonAlgo® Signal Contract: PRME PUT Expiry: 2026-05-15 | Strike: $3.00 | Type: PUT Option Plan (premium): Entry: $0.15 Stop: $0.11 TP1: $0.20 TP2: $0.26 TP3: $0.36 🔗 https://dragonalgo.com

0 · Reply

babyloncapital Apr. 16 at 4:33 PM

$PRME bruh move already

1 · Reply

Mcnulty_jimmy Apr. 16 at 2:24 PM

$PRME Daily Deion

0 · Reply

Elamenape2 Apr. 16 at 2:21 PM

$PRME

2 · Reply

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Mar 3, 2026, 8:00 AM EST - 6 weeks ago

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Feb 25, 2026, 8:00 AM EST - 7 weeks ago

Prime Medicine to Participate in Upcoming Investor Conferences

Jan 7, 2026, 8:00 AM EST - 3 months ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 7, 2025, 8:05 AM EST - 4 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Nov 25, 2025, 8:00 AM EST - 5 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 5 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 7, 2025, 10:21 AM EST - 5 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 5 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 8:01 AM EST - 5 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Oct 30, 2025, 4:01 PM EDT - 6 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 1, 2025, 4:01 PM EDT - 9 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 30, 2025, 9:33 PM EDT - 9 months ago

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 4:01 PM EDT - 9 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 16, 2025, 8:10 AM EDT - 9 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 9 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

May 19, 2025, 8:31 AM EDT - 11 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 11 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 2 years ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Upcoming Investor Conferences

Nov 3, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 27, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 22, 2023, 8:00 AM EDT - 3 years ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

StockMarketGuru Apr. 17 at 4:24 PM

$PRME oh?

0 · Reply

JasonCO Apr. 17 at 4:00 PM

$PRME

0 · Reply

Elamenape2 Apr. 17 at 3:54 PM

$PRME

0 · Reply

arg195 Apr. 17 at 3:09 PM

$PRME SPY up 7% past 6 months, PRME down 30% same period

1 · Reply

Mcnulty_jimmy Apr. 17 at 2:47 PM

$PRME Daily Deion

0 · Reply

Mindegap Apr. 17 at 2:37 PM

0 · Reply

DragonAlgo Apr. 17 at 8:37 AM

0 · Reply

babyloncapital Apr. 16 at 4:33 PM

$PRME bruh move already

1 · Reply

Mcnulty_jimmy Apr. 16 at 2:24 PM

$PRME Daily Deion

0 · Reply

Elamenape2 Apr. 16 at 2:21 PM

$PRME

2 · Reply

arg195 Apr. 16 at 2:18 PM

$PRME the offering will send this below 3 in a blink

0 · Reply

DragonAlgo Apr. 16 at 1:56 PM

🐉 $PRME CALL — DragonAlgo® Signal Contract: PRME CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.06 Stop: $0.04 TP1: $0.08 TP2: $0.10 TP3: $0.14 🔗 https://dragonalgo.com

0 · Reply

PorkchopSquats Apr. 16 at 1:24 PM

$PRME Daily candles, blue line is the 50MA. Bounced twice in two days. Historically performs well at least temporarily after a break and hold of the 5MA. Might be time for a test of the 200MA at $4.07.

0 · Reply